None listed
Conditions
Brief summary
The purpose of this trial is to investigate the dose-related effects of intraduodenal administration of the bitter agonist, quinine on energy intake at a subsequent ad libitum buffet style meal and for the remainder of the day, plasma gut hormone concentrations, blood glucose, appetite perceptions, and food preference in healthy individuals, We have found in one of our recent studies that quinine, given as a bolus in doses of 300 or 600 mg (in 10 ml water), potently slowed gastric emptying and lowered postprandial blood glucose. Moreover, we observed more potent blood glucose lowering effects when quinine was administered intraduodenally than intragastrically, suggesting that interaction of quinine with small intestinal receptors is required for potent effects. Therefore, based on these findings, this study aims to characterise the dose-related effects of intraduodenal quinine at these doses, on energy intake.
Interventions
Participants will receive in randomised, double-blind fashion, a 10-ml bolus of either (i) 600 mg quinine (ii) 300 mg quinine, (iii) water (control) intraduodenally on 3 separate visits. Each visit will be ~5 hours in duration, and separated by 3-7 days. In females, the study visits will be arranged in the 7-10 days from the start of their period cycle. Studies will be performed at the Clinical Research Facility, Adelaide Medical School, University of Adelaide, by staff and students trained in the required clinical research techniques. Participants will consume a standardised dinner meal, (400g McCain's beef lasagne), the night before each study visit by no later than 7pm. After fasting for ~13.5 hours overnight and refraining from alcohol and exercise for 24 hours, participants will arrive at the Clinical Research Facility by 8:15 am. Upon arrival, participants will be given a standardised light breakfast (1 slice (30 g) white bread, 10 g jam and a cup (200 ml) black tea; ~100 kcal), after which they will be intubated with a 17-channel manometric catheter (Dentsleeve, Mui Scientific) that will be inserted through an anaesthetised nostril and allowed to pass through the stomach and into the duodenum by peristalsis. The infusion port will be positioned ~ 14 cm distal to the pylorus. The correct positioning of the catheter will be monitored continuously by measurement of the transmucosal potential difference in the stomach (~ -40 mV) and the duodenum (~ 0 mV). Once the catheter has been positioned correctly, an intravenous cannula will be placed into a forearm vein for regular blood sampling. At 11.30 am, t = -30 min, a baseline blood sample (10 ml) will be taken, the participant will complete a validated 100-ml Visual Analogue Scale (VAS) questionnaire to assess appetite-related perceptions and gastrointestinal (GI) symptoms as well as the Leeds Food Preference Questionnaire, which is a computerised behavioural task that provides measures of 'liking' and 'wanting' components of food preference and food reward. Immediately thereafter (t = -30 min), participants will receive either (i) 600 mg quinine, (ii) 300 mg quinine, (iii) water into the duodenum. 10-ml blood samples for the measurement of plasma concentrations of hormones and glucose will be collected every 10 min (-20, -10, 0), and participants complete VAS questionnaires. Participants will complete Leeds Food Preference Questionnaire once immediately before quinine administration (t=-30) and once 30 minutes later, immediately before the buffet meal (t=-1). Participants will be presented with the buffet meal (t=0) which comprises of 4 slices (~120 g) of whole-meal bread, 4 slices (~120 g) of white bread, 100 g sliced ham, 100 g sliced chicken, 85 g sliced cheddar cheese, 100 g lettuce, 100 g sliced tomato, 100 g sliced cucumber, 22 g mayonnaise, 20 g margarine, 1 apple (~170 g), 1 banana (~190 g), 175 g vanilla yogurt, 100 g chocolate custard, 120 g fruit salad, 375 mL iced coffee, 300 mL orange juice, and 600 mL water and has a total energy content of ~2300 kcal (~27% fat, ~52% carbohydrate, and ~21% protein) and weight of ~2924. Participants will be allowed 30 min to freely consume the meal until comfortably full. Immediately after the meal (t = 30 min) and then every 30 min (t = 60 and 90 min), blood samples will be collected and participants complete VAS questionnaires. At t = 90 min, the intravenous cannula will be removed, and participants will be allowed to leave the laboratory.
Sponsors
Study design
Eligibility
Inclusion criteria
Healthy
Exclusion criteria
-regular gastrointestinal symptoms or significant gastrointestinal disease -previous gastrointestinal surgery (other than gallbladder removal) -use of prescribed or non-prescribed medications (including vitamins and herbal supplements) which may affect energy metabolism, gastrointestinal function, body weight or appetite (e.g. domperidone, anticholinergic drugs (e.g. atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.) -substantial daily consumption of quinine, e.g. as part of quinine-based anti-malaria treatment (irregular consumption of small amounts of quinine, e.g. in tonic water, is acceptable) -regular medication that may affect any of the study outcomes (i.e. gastrointestinal motor or hormone function) and cannot be discontinued during the study -using contraceptive pills, injections, IUD -other food allergy -current gallbladder or pancreatic disease -coagulation abnormalities -oesophageal varices or strictures -cardiovascular or respiratory diseases that may affect any of the study outcomes and/or tolerance of the naso-duodenal tube -all types of epilepsy -individuals with low ferritin levels (females <15 ng/mL, males <30 ng/mL), or who have donated blood in the 12 weeks prior to taking part in the study -any other illnesses as assessed by the investigator (including chronic illnesses that may affect any of the study outcomes and not explicitly listed above) -high performance athletes, due to their specific dietary requirements and energy intakes (i.e. much higher than the average population), which affect gastrointestinal functions -current intake of > 2 standard alcoholic drinks on > 5 days per week, due to the known effects of alcohol on gastrointestinal function -current smokers/users of tobacco products (including pipe, chewing, cigarettes, cigars, sheesha, vaping) -recreational drug use (e.g. marijuana) -current intake of any illicit substance (since all of these, i.e. tobacco products, marijuana and illicit drugs may affect gastrointestinal functions) -vegetarians -inability to tolerate naso-gastric tube -inability to comprehend study protocol -in premenopausal females, pregnancy, lactation or surgical sterilisation (a pregnancy test will be performed, using a urine sample, on the morning of study day -female participants with self-reported irregular period cycles (since studies will be performed during the follicular phase, to avoid any influences of the different stages of the menstrual cycle on study outcomes)